Breakthrough Pain - Fast-acting players will capture majority market share

Questions: Discounts, Updates etc.

Price: $11,400.00

Publication Date: 2006-11-15

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

In spite of generic Actiq competition, Cephalon’s reign of the breakthrough pain market will be secured in the short-term with sales of its follow-on brand Fentora. From 2008, however, a number of fast-acting analgesics will enter the arena and battle for market share; this and other growth drivers will see the market more than double from 2005 to reach an estimated $2.5 billion in 2016.


Scope

  • Discussion and quantification of the patient potential and market size of breakthrough pain in both malignant and non-malignant diseases
  • Assessment of the unmet clinical needs in breakthrough pain as validated by interviewed international opinion leaders
  • Detailed overview and assessment of key drugs in Phase II and above clinical development, including Fentora, Rapinyl, and BEMA Fentanyl
  • Ten-year sales forecasts to 2016 for key pipeline products


    • Report Highlights
    Relatively high unmet clinical need, additional patient groups, the launch of new products, and no further key patent expiries within the next ten years will see the breakthrough pain market more than double from 2005 to reach $2.5 billion in 2016.

    As well as for oral transmucosal fentanyl products, opportunities also exist for non-oral analgesics. Intranasal and inhaled technology may provide convenient and fast acting analgesia and are potentially suitable for self-administration in the lucrative outpatient setting.

    A key growth strategy will be to gain initial approval for cancer breakthrough pain and then drive sales in additional indications through off-label use or regulatory approval. Key non-malignant applications for fast acting analgesics include breakthrough pain in post-operative pain, chronic low back, and osteoarthritic pain.


    Reasons to Purchase

  • Explore the strategies that have made Cephalon the market leading company in breakthrough pain
  • Examine the potential for intranasal and inhaled analgesics and what other factors companies are using to differentiate their products
  • Analyze the competitive environment at the time of product launch and identify lucrative gaps in the market

    • Table of Contents

    Other users found this report page using the following search terms: pain breakthrough pain pain breakthrough acting fast market fentanyl fentora actiq opioids rapinyl

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.


    Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.